Nutritional Supplementation to Improve Colorectal Cancer Surgery (NUTRICOLOR)
Perioperative Nutritional Supplementation to Prevent Postoperative Complications and Improve Postoperative Outcomes After Colorectal Cancer Surgery: a Single-center Unblinded Randomized Controlled Trial
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Annalisa Maroli, PhD
- Número de telefone: 00390282247776
- E-mail: annalisa.maroli@humanitas.it
Estude backup de contato
- Nome: Stefano De Zanet, MS
- Número de telefone: 00390282244623
- E-mail: stefano.dezanet@humanitas.it
Locais de estudo
-
-
Milano
-
Rozzano, Milano, Itália, 20089
- Irccs Humanitas Research Hospital
-
Investigador principal:
- Antonino Spinelli, MD, PhD
-
Contato:
- Annalisa Maroli, PhD
- Número de telefone: 00390282247776
- E-mail: annalisa.maroli@humanitas.it
-
Contato:
- Stefano De Zanet, MS
- Número de telefone: 00390282244623
- E-mail: stefano.dezanet@humanitas.it
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion criteria
- Participants aged more than 18 years old.
- Histological diagnosis of colorectal adenocarcinoma.
- Participants scheduled for elective minimally invasive colorectal resection.
- Participants with a preoperative MUST score equal to or below 2. Exclusion criteria
- Any condition that, in the opinion of the investigator, may interfere with the study procedures.
- Emergent surgery.
- Planned open surgery. Participants undergoing unplanned surgical conversion (from minimally invasive to open) will be withdrawn from the study.
- Any concomitant surgery unrelated to the primitive colorectal cancer (for example, concomitant liver metastasis resection).
- Participants with preoperative MUST score > 2.
- Pregnant or breastfeeding participants. Women of childbearing potential must agree to use a reliable contraceptive method. Otherwise, a pregnancy urine test must be performed at each study visit to exclude a potential pregnancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Diet optimization (DO)
Dietary optimization will include a tailored diet to maintain or restore a good nutritional status, body composition (e.g.
weight or lean mass gain if necessary), and macro/micronutrient intake in case of deficiencies detected during the nutritional screening.
Participants will be instructed to follow the dietary indications throughout the study, with appropriate adjustments according to following nutritional assessments.
|
Dietary optimization will include a tailored diet to maintain or restore a good nutritional status, body composition (e.g.
weight or lean mass gain if necessary), and macro/micronutrient intake in case of deficiencies detected during the nutritional screening.
Participants will be instructed to follow the dietary indications throughout the study, with appropriate adjustments according to following nutritional assessments.
|
|
Experimental: Diet Optimization and Oral Nutritional Supplementation (DO+ONS)
Participants in the DO+ONS arm will receive dietary optimization and standardized oral nutritional supplementation designed according to the ESPEN guidelines.
The treatment will start 14 days before surgery and will be restored the day after surgery for the following 60 days.
|
Dietary optimization will include a tailored diet to maintain or restore a good nutritional status, body composition (e.g.
weight or lean mass gain if necessary), and macro/micronutrient intake in case of deficiencies detected during the nutritional screening.
Participants will be instructed to follow the dietary indications throughout the study, with appropriate adjustments according to following nutritional assessments.
ONS will consist of LH Blu® (Lionhealth Italia Srl).
LH Blu® is categorized as a food for special medical purposes and is indicated for the treatment of malnourished patients.
ONS will start 14 days before the planned intervention with a tailored dosage decided according to the malnutrition risk (low vs medium).
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative complications
Prazo: 30 days from surgery
|
The rate of postoperative complications occurring within 30 days from surgery
|
30 days from surgery
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative septic complications
Prazo: 30 days from surgery
|
The rate of postoperative septic complications occurring within 30 days from surgery.
Septic complications are defined according to the criteria proposed by the International Sepsis Definitions Conference and include documented postoperative extra-intestinal infections- such as urinary tract infections and pneumonia-, intra-abdominal septic complications- such as anastomotic leaks, pelvic abscesses, and peritonitis-, surgical site infections, and systemic symptoms of abnormal inflammatory response- such as fever higher than 38°C or C-Reactive Protein (CRP) increase higher than 200 mg/dL for more than two consecutive days
|
30 days from surgery
|
|
Comprehensive Complication Index (CCI)
Prazo: 30 days from surgery
|
The median Comprehensive Complication Index (CCI) computed from all postoperative complications that occurred within 30 days from surgery.
The CCI ranges from 0 to 100, where 0 indicates the best outcome (no postoperative complications), and 100 indicates the worst outcome (postoperative complications leading to death).
|
30 days from surgery
|
|
Length of hospital stay
Prazo: 30 days from surgery
|
The median length of hospital stay calculated in days from the day after surgery until the day of discharge
|
30 days from surgery
|
|
Hospital readmission
Prazo: 30 days from surgery
|
The rate of hospital readmissions- including ward readmission and emergency room accesses- within 30 days from surgery
|
30 days from surgery
|
|
Sarcopenia
Prazo: Six months after surgery
|
The proportion of participants with sarcopenia six months after surgery.
Sarcopenia will be assessed from the Skeletal Muscle Index (SMI) computed from the abdominal Computed Tomography (CT) scans collected at screening and 6 months after surgery.
SMI less than 7.0 kg/m2 for men and less than 5.5 kg/m2 for women will be considered indicative of sarcopenia.
|
Six months after surgery
|
|
Normal weight
Prazo: 60 days after surgery
|
The proportion of participants with normo-weight Body Mass Index (BMI) measures at 60 days after surgery.
Normal BMI values ranges from 18.5 Kg/m2 and 24.9 Kg/m2.
|
60 days after surgery
|
|
Mini Nutritional Assessment (MNA) score
Prazo: 60 days after surgery
|
The median Mini Nutritional Assessment (MNA) score collected 60 days after surgery.
The MNA score ranges from 0 (worst possibile nutritional status) to 30 (best possible nutritional status).
|
60 days after surgery
|
|
EuroQoL-5 Dimension- 5 Levels (EQ5D5L) score
Prazo: 60 days after surgery
|
The median EuroQoL-5 Dimension- 5 Levels (EQ5D5L) score collected 60 days after surgery.
The EQ5D5L score ranges from 0 (worst possible perceived health) to 25 (best possible perceived health).
|
60 days after surgery
|
|
Proctitis
Prazo: Six months after surgery
|
The proportion of participants with clinical signs of active proctitis six months after surgery.
Active proctitis will be assessed through rigid or flexible sigmoidoscopy and will be defined by the presence of any of the following findings: friable mucosa with edema, oozing, or ulcerations; bleeding; wall thickening; pseudopolyps; strictures; stenosis; loss of normal curvature; necrosis; perforations; fistula.
The severity of proctitis will be classified using the RTOG/EORTC grading system
|
Six months after surgery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Antonino Spinell, MD, PhD, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Intestinais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Intestinais
- Doenças retais
- Doenças do cólon
- Neoplasias Colorretais
- Comida
- Dieta, comida e nutrição
- Fenômenos fisiológicos
- Comida e bebidas
- Suplementos alimentares
Outros números de identificação do estudo
Outros números de identificação do estudo
- CHR1-11-2025
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .